Results 31 to 40 of about 13,488 (162)

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials

open access: yes, 2022
Objective: To compare the inhibition of LAG3-PD1 versus the inhibition of CTLA-4-PD1 in patients with previously untreated advanced melanoma. Methods: The individual participant data (IPD) were extracted from the KM plots using a graphical reconstructive
Chen, Guo-Ming   +19 more
core   +1 more source

Flynn, T T, 7159

open access: yes, 2017
This record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete.
Australian Red Cross Society, National Office
core  

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

open access: yes, 2021
Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma.
David Hogg   +12 more
core   +1 more source

PD1 inhibitor induced inverse lichenoid eruption: a case series

open access: yes, 2020
The increased use of monoclonal antibodies that target the immune checkpoint T cell receptor programmed death-1 (PD1) to treat numerous solid tumors has led to several reports describing associated cutaneous adverse events.
Garg, Vaibhav   +4 more
core   +2 more sources

Control of PD1 by NOD2.

open access: yes, 2023
We provide evidence here from loss-of-function studies in mice and gain-of-function studies in human cells (1, 2) which demonstrate control of PD1, encoded by PDCD1, by the NLR (nucleotide-binding oligomerization domain-like receptor) family protein NOD2.
Shahan Mamoor
core   +1 more source

PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease

open access: yes, 2010
Regulatory T lymphocytes (T-reg) play a fundamental importance in modulating the relative balance between inflammation and immune tolerance, and alterations of these cells are observed in inflammatory diseases.
A. Gatti   +15 more
core   +1 more source

Clinical significance of PD1 and PDL1 in human breast cancer [PDF]

open access: yes, 2017
Background/Aim: Programmed death 1 (PD1) and its ligand programmed death ligand 1 (PDL1) form a pathway which when activated is thought to result in suppression of antitumor adaptive responses, influencing antitumor immunity.
Owen, Sioned   +6 more
core   +1 more source

A Comparative Grammar of the Early Germanic Languages

open access: yes, 2018
Fulk’s Comparative Grammar offers an overview of and bibliographical guide to the study of the phonology and the inflectional morphology of the earliest Germanic languages, with particular attention to Gothic, Old Norse / Icelandic, Old English, Old ...
R.D. Fulk
core   +1 more source

Literary Impressionisms

open access: yes, 2018
This book aims to locate and draw out resonances of impressionism in Swedish and Finland-Swedish prose at the end of the nineteenth century, a field hitherto overlooked in the critical debate on literary impressionism.
Storskog, Camilla, Camilla Storskog
core   +2 more sources

Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor

open access: yes, 2016
The durability and efficacy of anti-human PD1 monoclonal antibodies (PD1 mAb) vary across different malignancies. Although an absence of tumor-infiltrating cytotoxic T lymphocytes has been identified as a cause for resistance to PD1 mAb, the presence of ...
Stephen J. Blake   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy